207_Combined course Presentations
Scope trial: update
Exclusive RT-CT (contemporary series) 3-yr OS: 47.2%
Prognostic factors: - Radiation dose - Cisplatin intensity
Crosby, BJC, 2017, 116: 709-716
Made with FlippingBook
Scope trial: update
Exclusive RT-CT (contemporary series) 3-yr OS: 47.2%
Prognostic factors: - Radiation dose - Cisplatin intensity
Crosby, BJC, 2017, 116: 709-716
Made with FlippingBook